LAG3 and neoplasm: Assessment of the expression of programmed death-1 (PD-1), lymphocyte activation gene-3 (LAG-3), and T cell immunoglobulin-3 (TIM-3) on tumor cells and their receptors on immune cells by immunohistochemical analysis, revealed that high expression of these molecules is associated with a lower response to CTL019 therapy [52].